"A full HTA is not recommended. The NCPE recommends that nivolumab as monotherapy or in combination with ipilimumab not be considered for reimbursement for this indication at the submitted price." [For advanced, unresectable or metastatic melanoma] (National Centre for Pharmacoeconomics, Ireland) Sep 30, 2026
HEOR • Melanoma • Oncology
|